Marcia S. Brose
Thomas Jefferson University · 280 works · 21,836 citations · h-index 55
Top works
- BRAF and RAS mutations in human lung cancer and melanoma.
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
- Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
- Cabozantinib in Progressive Medullary Thyroid Cancer
- Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
- Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study